Semaglutide

SAN CARLOS, Calif., August 13, 2026 Biomea Fusion, Inc. announced that the first participant has been dosed in a...

Shanghai, China, August 12, 2026 Aurisco Pharmaceutical announced that its manufacturing site in Yangzhou, China, has successfully passed a...

Miami, Florida, August 10, 2026 Veru Inc. has announced full enrollment of 239 patients in its Phase 2b PLATEAU...

Bagsværd, Denmark, August 5, 2026 Novo Nordisk has secured a significant legal victory after the District Court of The...

COPENHAGEN, Denmark, July 28, 2026 Antag Therapeutics announced that the first patient has been dosed in its Phase 2a...

MIAMI, Fla., July 27, 2026 Veru Inc. announced the successful completion of patient enrollment in its Phase 2b PLATEAU...

BAGSVÆRD, Denmark, July 15, 2026 Novo Nordisk has achieved a major regulatory milestone after the European Commission (EC) granted...

ALAMEDA, Calif., July 7, 2026 Vivani Medical, Inc. has entered into a new strategic agreement with Novo Nordisk to...

MEQUON, Wis., July 7, 2026 Vector Science & Therapeutics Corp. has entered into a landmark exclusive licensing and cGMP...

TORONTO, Ontario, June 30, 2026 Apotex Health Corp. announced that Health Canada has approved SEVMIA™ (semaglutide injection), making it...